Eribulin reverses EMT and increases tumour
exposure to the Immune System in MBC
Goto W, et al.,
AACR
2016 (abstract 5127).
• 52 patients with locally advanced or metastatic breast cancer treated
with eribulin
• Correlated response rate (RR) with immunohistochemical evaluation:
o
TILS: PD-1, CD8, FOXP3
o
Cancer cells: PD-L1, PD-L2
o
EMT markers: E-cadherin, N-cadherin, vimentin, CA9
Conclusions
•
Statistically significant correlations
between clinical RR and change in
marker status for
PD-L1 (p = 0.024)
FOXP3 (p = 0.004)
E-cadherin (p = 0.004)
CA9 (p = 0.024)
•
Immune suppression markers
(PD-L1, FOXP3) going negative
correlated with
Clinical RR
Reversal of EMT (E-cadherin going up)
•
Loss of hypoxia (CA9 going down)
correlated with clinical RR
